Tevogen Bio Set to Join Russell 3000® Index
2024年6月13日 - 4:45AM
Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq:
TVGN), a clinical-stage specialty immunotherapy biotech pioneer
developing off-the-shelf, genetically unmodified T cell
therapeutics in oncology, neurology, and virology, is set to join
the broad-market Russell 3000® Index at the conclusion of the 2024
Russell US Indexes annual reconstitution, effective at the open of
US equity markets on Monday, July 1, according to a preliminary
list of additions posted Friday, May 24.
The annual Russell US Indexes reconstitution
captures the 4,000 largest US stocks as of Tuesday, April 30,
ranking them by total market capitalization. Membership in the US
all-cap Russell 3000® Index, which remains in place for one year,
means automatic inclusion in the large-cap Russell 1000® Index or
small-cap Russell 2000® Index as well as the appropriate growth and
value style indexes. FTSE Russell determines membership for its
Russell indexes primarily by objective, market-capitalization
rankings, and style attributes.
“We are pleased to be included in the Russell Index
and welcome the increased visibility by the investment community as
we remain committed to driving scientific and business excellence.
Our mission, to offer personalized T cell therapeutics which are
economically viable, should benefit patients while our commercially
attractive model should benefit institutional and retail investor
alike,” commented Dr. Ryan Saadi, Tevogen Bio Founder and CEO.
Russell indexes are widely used by investment
managers and institutional investors for index funds and as
benchmarks for active investment strategies. According to the data
as of the end of December 2023, about $10.5 trillion in assets are
benchmarked against the Russell US indexes, which belong to FTSE
Russell, a prominent global index provider.
Fiona Bassett, CEO of FTSE Russell, an LSEG
Business, comments, “Russell indexes–now in their 40th
year–continue to evolve to reflect the dynamic US economy. Annual
rebalancing plays a vital role in establishing accurate benchmarks,
ensuring they correctly mirror their designated market segments and
remain unbiased in terms of size and style.”
For more information on the Russell 3000® Index and
the Russell indexes reconstitution, go to the “Russell
Reconstitution” section on the FTSE Russell website.
About Tevogen Bio
Tevogen is a clinical-stage specialty immunotherapy
company harnessing one of nature’s most powerful immunological
weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf,
genetically unmodified precision T cell therapies for the treatment
of infectious diseases, cancers, and neurological disorders, aiming
to address the significant unmet needs of large patient
populations. Tevogen Leadership believes that sustainability and
commercial success in the current era of healthcare rely on
ensuring patient accessibility through advanced science and
innovative business models. Tevogen has reported positive safety
data from its proof-of-concept clinical trial, and its key
intellectual property assets are wholly owned by the company, not
subject to any third-party licensing agreements. These assets
include three granted patents and twelve pending patents, two of
which are related to artificial intelligence.
Tevogen is driven by a team of highly experienced
industry leaders and distinguished scientists with drug development
and global product launch experience. Tevogen’s leadership believes
that accessible personalized therapeutics are the next frontier of
medicine, and that disruptive business models are required to
sustain medical innovation.
About FTSE Russell
FTSE Russell is a leading global provider of
benchmarking, analytics, and data solutions for investors, giving
them a precise view of the market relevant to their investment
process. A comprehensive range of reliable and accurate indexes
provides investors worldwide with the tools they require to measure
and benchmark markets across asset classes, styles, or
strategies.
FTSE Russell index expertise and products are used
extensively by institutional and retail investors globally. For
over 30 years, leading asset owners, asset managers, ETF providers
and investment banks have chosen FTSE Russell indexes to benchmark
their investment performance and create ETFs, structured products,
and index-based derivatives.
FTSE Russell is focused on applying the highest
industry standards in index design and governance, employing
transparent rules-based methodology informed by independent
committees of leading market participants. FTSE Russell fully
embraces the IOSCO Principles, and its Statement of Compliance has
received independent assurance. Index innovation is driven by
client needs and customer partnerships, allowing FTSE Russell to
continually enhance the breadth, depth and reach of its
offering.
FTSE Russell is wholly owned by London Stock
Exchange Group.
For more information, visit
https://www.lseg.com/en/ftse-russell.
Contacts
Tevogen Bio CommunicationsT: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
Tevogen Bio (NASDAQ:TVGN)
過去 株価チャート
から 8 2024 まで 9 2024
Tevogen Bio (NASDAQ:TVGN)
過去 株価チャート
から 9 2023 まで 9 2024